Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Prostatic Neoplasms 47Lung Neoplasms 43Neoplasm Metastasis 34Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 26Multiple Myeloma 24Glioma 22Pancreatic Neoplasms 21Carcinoma, Renal Cell 21Lymphoma, Large B-Cell, Diffuse 20Ovarian Neoplasms 19Melanoma 19Glioblastoma 19Squamous Cell Carcinoma of Head and Neck 18Lymphoma 18Urinary Bladder Neoplasms 17Colorectal Neoplasms 17Oropharyngeal Neoplasms 15Mouth Neoplasms 15Triple Negative Breast Neoplasms 14Brain Neoplasms 14Fallopian Tube Neoplasms 13Carcinoma 13Laryngeal Neoplasms 12Carcinoma, Hepatocellular 12Astrocytoma 12Leukemia, Myeloid, Acute 11Sarcoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Neuroblastoma 10

Interventions

Vincristine 7Cyclophosphamide 7Methotrexate 6Dexamethasone 6Cytarabine 6merphos 5Mercaptopurine 5Doxorubicin 5pegaspargase 4dexamethasone acetate 4dexamethasone 21-phosphate 4blinatumomab 4azathiopurine 4auricularum 4Prednisone 4Leucovorin 4Inotuzumab Ozogamicin 4Calcium Dobesilate 4prednylidene 3deltacortene 3Thioguanine 3Specimen Handling 3N,N-dicyclohexyl-isoborneol-10-sulfonamide 3Methylprednisolone 3Asparaginase 3calaspargase pegol 2asparaginase erwinia chrysanthemi recombinant 2Spinal Puncture 2Rituximab 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × Magnetic Resonance Spectroscopy × 90 days × Clear all
NCT03504644 2026-05-29

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Eastern Cooperative Oncology Group

Phase 1/2 Active not recruiting
40 enrolled 18 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡